Application of Tibetan medicine fructus terminaliae billericae extract in preparation of medicine for treating non-alcoholic fatty liver disease

By establishing a mouse model of non-alcoholic fatty liver, and examining the prevention and treatment effects of extracts from different parts of Mauer, it was found that ethyl acetate extracts have significant prevention and treatment effects on NAFLD, which solved the problem of lack of effective treatment of NAFLD in the prior art. It achieves the effect of reducing liver fat accumulation and inflammation.

CN119015329APending Publication Date: 2024-11-26SOUTHWEST UNIVERSITY FOR NATIONALITIES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310607026.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

There is no effective drug for the treatment of non-alcoholic fatty liver (NAFLD) in the prior art, and the effective site of Mauerzi in treating liver disease is not clear.

Method used

The non-alcoholic fatty liver mouse model was established through CDAHFD feed modeling, and the prevention and treatment effect of extracts from different parts of Mauhose on NAFLD was investigated. The specific use of ethanol at more than 95% concentration was extracted, followed by water-petroleum ether, water-n-butanol , water-ethyl acetate solvent system is extracted to obtain ethyl acetate extract, which is used to prepare drugs for preventing or treating NAFLD.

Benefits of technology

Maukozone ethyl acetate extract significantly reduced the serum ALT, AST, TG, and LDL-C levels in mice, improved liver fat accumulation and inflammatory cell infiltration, proving that it has a preventive and therapeutic effect on NAFLD, and the main active ingredient exists in the ethyl acetate site .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004250911260000011
    Figure HDA0004250911260000011
  • Figure HDA0004250911260000012
    Figure HDA0004250911260000012
  • Figure HDA0004250911260000021
    Figure HDA0004250911260000021
Patent Text Reader

Abstract

The invention provides an application of a belleric terminalia fruit ethyl acetate extract in preparation of a medicine for preventing or treating non-alcoholic fatty liver, finds an active site for Tibetan medicine belleric terminalia fruit, and has a promotion effect on deep research and development of belleric terminalia fruit.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medicine and phytochemistry. Background Art

[0002] Nonalcoholic fatty liver disease (NAFLD) refers to a clinical pathological syndrome characterized by fatty degeneration and storage of hepatic parenchymal cells, excluding alcohol and other clear liver-damaging factors. It has become a global public health problem. [i] As people's living standards continue to improve, the incidence of the disease has increased year by year and has gradually become younger. It has become the second largest liver disease after viral hepatitis. [ii] The occurrence of NAFLD is related to multiple factors such as genetics, bad living habits, metabolic disorders, etc. Recent studies have also found that the disease can develop into cirrhosis or even liver cancer in the later stages. [iii] Modern medical research believes that the pathogenesis of NAFLD is the "second hit" theory, but there is no effective treatment drug in clinical practice. [iv] .

[0003] Terminaliae belliricae Frutus is a dried mature fruit of the plant Terminaliae belliricae Frutus of the Combretaceae family. It is distributed in small quantities in Tibet and Yunnan in my country. It is a commonly used medicinal material that can clear away heat and detoxify, astringe and nourish blood, and harmonize various medicines. [v] The chebula is one of the "three fruits" in Tibetan medicine. It contains a variety of chemical components such as polyphenols, tannins and flavonoids, and has anti-inflammatory, antibacterial, anti-tumor and other pharmacological effects. The chebula is a classic Tibetan medicine for the treatment of liver diseases, "Twenty-five Flavors of Turquoise Pills". [vi] And the important ingredients of "Shiwei Terminalia Powder" [vii] . Jadon [viii] The research of et al. believes that Terminalia chebula has a good protective effect on the liver and can promote liver repair and regeneration. Summary of the invention

[0004] From the existing research, it is not clear that the effective part of Terminalia chebula for treating liver disease. The present invention will establish a non-alcoholic fatty liver mouse model by CDAHFD feed modeling, investigate the preventive and therapeutic effects of extracts from different parts of Terminalia chebula on the disease, and determine the effective part of Terminalia chebula for preventing and treating NAFLD by measuring mouse serum indicators and observing liver pathological changes.

[0005] Specifically, the present invention provides use of the ethyl acetate extract of Terminalia chebula in preparing a medicament for preventing or treating non-alcoholic fatty liver disease.

[0006] Wherein, the preparation method of the ethyl acetate extract is as follows:

[0007] Take the Terminalia chebula, extract with ethanol with a concentration of more than 95%, recover ethanol from the alcohol extract, and then extract with water-petroleum ether, water-n-butanol and water-ethyl acetate solvent systems in sequence, take the ethyl acetate part, and remove the solvent to obtain the product.

[0008] The specific operation of ethanol extraction is: use 95% ethanol in an amount 10 times the mass of Terminalia chebula to extract Terminalia chebula powder, extract 2-3 times, each time for 30 to 180 minutes.

[0009] Wherein, the drug is a drug that reduces the levels of ALT, AST, TG, and LDL-C.

[0010] Wherein, the drug is a drug for reducing liver fat accumulation.

[0011] Wherein, the drug is a drug for improving liver damage.

[0012] Wherein, the drug is a drug for reducing liver fat vacuoles and inflammatory cell infiltration. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 AST and ALT levels of mice in each group

[0014] Figure 2 Oil red O staining of liver of mice in each group

[0015] Figure 3 HE staining of liver pathological sections of mice in each group DETAILED DESCRIPTION

[0016] Example 1

[0017] 1.1 Materials

[0018] 1.1.1 Drugs

[0019] Terminalia chebula (purchased from Chengdu Lotus Pond Chinese Medicinal Materials Market) was identified as the dried mature fruit of Terminalia bellirica (Gaertn.) Roxb. of the Combretaceae family by Associate Professor Gong Puyang of the School of Pharmacy of Southwest University for Nationalities; Silymarin Capsules (B.S. Ma Pharmaceutical Factory, Germany, batch number B1903202).

[0020] 1.1.2 Reagents and instruments

[0021] Choline-deficient, L-amino acid defined, high fat diet (CDAHFD, batch number: TP36225MCD) and control feed (MCS, batch number: TP36225MCS) were purchased from Nantong Trofi Feed Technology Co., Ltd.; aspartate aminotransferase (AST, product number C010-2-1) and alanine aminotransferase (ALT, product number C009-2-1) were purchased from Nanjing Jiancheng Bioengineering Research Institute; petroleum ether (60-90) (Petroleum ether60-90, production batch number: 2021090901), ethyl acetate (Ethyl acetate, product number: 1000-1000-1000) and 1,2-dihydropyrrolidone (1,6-dihydropyrrolidone) were purchased from Nanjing Jiancheng Bioengineering Research Institute. acetate, production batch number: 2021081701), anhydrous ethanol (Ethanol, production batch number: 2021110402), and n-butanol (n-Butanol) were all purchased from Chengdu Cologne Chemical Co., Ltd.; H1650-W centrifuge (Hunan Xiangyi Experimental Instrument Development Co., Ltd.); xiande-2000A rotary evaporator (Shanghai Xiande Experimental Instrument Co., Ltd.); pipette (Germany Aibend AG model: J38918H); Cytation 5 multi-function microplate reader (US Bio-Tek, model CYT5M).

[0022] 1.1.3 Animals

[0023] Animal license number SCXK (Chuan) 2020-034, SPF-grade C57BL / 6 mice (male, 35 days old) were purchased from Chengdu Dashuo Experimental Animal Co., Ltd.; breeding conditions: constant temperature 22-25°C, constant humidity 40-60%, light and dark cycle every 12 h, and adaptive breeding for one week (given ordinary sterile feed).

[0024] 1.2 Experimental methods

[0025] 1.2.1 Extraction of different chemical parts of Terminalia chebula

[0026] 500g of dried Terminalia chebula was crushed into fine powder. Extract Terminalia chebula powder with 10 times the amount of 95% ethanol, 1 hour each time, for a total of two extractions, and filter after the extraction is completed. Combine the two filtrates, concentrate them with a rotary evaporator at 60°C for 1 hour, and the concentrated solution is the ethanol extract after drying. Take the dried concentrate, add an appropriate amount of purified water to dissolve, and extract. Add petroleum ether, n-butanol, and ethyl acetate to the solution for extraction (when the organic layer is almost colorless, the next extractant can be replaced), and different extracts are obtained, that is, the extracts of different parts of Terminalia chebula.

[0027] 1.2.2 Animal grouping, modeling and drug administration

[0028] 1.2.2.1 Grouping

[0029] Eighty male C57BL / 6 mice were randomly divided into normal control group, model group, ethanol extract of Terminalia bellirica (EETB), petroleum ether extract of Terminalia bellirica (PETB), ethyl acetate extract of Terminalia bellirica (EETB), n-butyl alcohol extract of Terminalia bellirica (BTB), water extract of Terminalia bellirica (WTB) and positive drug control group (Silymarin), with 10 mice in each group.

[0030] 1.2.2.2 Modeling

[0031] The blank group was fed with a control diet (MCS), and the other groups were fed with a choline-deficient, L-amino acid defined high-fat diet (CDAHFD). The diet was induced to establish a NAFLD mouse model for 6 weeks.

[0032] 1.2.2.3 Administration

[0033] The dosage was calculated according to the provisions of the 2020 Chinese Pharmacopoeia and the "Equivalent Metrics of Human and Animal Surface Areas". The extracts from different parts of Terminalia chebula were diluted with purified water to obtain a drug with a concentration of 0.18 g / kg. The concentration of the positive drug group was 8.4 mg / kg, and the dosage volume was 0.2 ml / 20 g. At the same time as modeling, mice in different groups were gavaged with drugs. Except for the blank group and the model group, which were gavaged with purified water, the mice in the other groups were gavaged with the corresponding drugs.

[0034] 1.2.3 Sample collection

[0035] After the last administration, the eyeballs of the mice were removed to collect blood and the complete liver tissue of the mice was removed, and the wet weight of the liver was weighed. The liver was then cleaned with saline, and part of the liver tissue was cut (the same part should be cut from all mice) and fixed in paraformaldehyde for subsequent experiments, and the remaining liver tissue was stored in a -80℃ refrigerator.

[0036] 1.2.4 Index detection

[0037] 1.2.4.2 Serum index detection

[0038] Blood was collected from the eyeball of mice, and after standing for 2 hours, it was centrifuged (the centrifuge speed was 3500 rpm, and the centrifugation time was 10 minutes). The supernatant was taken and the AST and ALT contents were determined.

[0039] 1.2.4.3 Pathological observation of liver tissue and Oil Red O staining of liver tissue

[0040] The liver tissue fixed with paraformaldehyde was obtained, processed as required, and then stained with HE and Oil Red O to observe the pathological changes of the liver and the fat accumulation in the liver.

[0041] 1.2.4.4 Statistical analysis

[0042] The software used for statistical analysis was GraphPad Prism 8. One-way ANOVA was used for data processing of three or more groups, and one-way analysis of variance was performed between groups. The final results were expressed as x±s.

[0043] 1.3 Experimental Results

[0044] 1.3.1 Effects of different extraction parts of Terminalia chebula on serum biochemical parameters of NAFLD mice

[0045] Compared with the blank group, the serum ALT, AST, TG, and LDL-C levels of the mice in the model group were significantly increased (P < 0.001), and the HDL-C was significantly decreased (P < 0.001), which indicated that CDAHFD induced liver function damage and lipid metabolism disorders in mice. Compared with the model group, the ALT, AST, TG, and LDL-C levels of the ethanol extract group and the ethyl acetate group were significantly decreased (P < 0.01), and HDL-C was significantly increased. The petroleum ether part can significantly reduce the ALT level of the model mice and increase the HDL-C content. The n-butanol part can significantly reduce the TG content of NAFLD mice. The above results show that different parts of Terminalia chebula have different degrees of improvement on NAFLD mice, among which the ethyl acetate part is its main active part against NAFLD, see Figure 1 .

[0046] 1.3.2 Improvement of liver fat accumulation in NAFLD mice by different extraction parts of Terminalia chebula

[0047] The results of Oil Red O staining showed that there was almost no fat accumulation in the blank group. Compared with the blank group, a large number of red lipid droplets appeared in the model group, indicating fat accumulation. After treatment with different extracts of Terminalia chebula and silymarin, the fat accumulation of each group was improved to varying degrees compared with the model group. Among them, the ethanol extract group, petroleum ether part, ethyl acetate part and positive drug group had better improvement effects. Figure 2 The above results indicate that the petroleum ether and ethyl acetate extracts of Terminalia chebula may improve liver fat accumulation in NAFLD mice.

[0048] 1.3.3 Effects of different extraction parts of Terminalia chebula on pathological changes in liver tissue of NAFLD mice

[0049] The staining results showed that the liver cells in the blank group had normal morphology, clear nucleus and cytoplasm staining, and no inflammatory cell infiltration and fat vacuoles accumulation. Compared with the blank group, the model group had a large number of fat vacuoles and inflammatory cell infiltration. Compared with the model group, the ethanol extract of Terminalia chebula, the ethyl acetate part of Terminalia chebula and the positive drug group showed a decrease in inflammatory cell infiltration, as shown in the figure. Figure 3 The above results indicate that the ethyl acetate fraction of Terminalia chebula can improve liver damage in NAFLD mice.

[0050] 2 Summary

[0051] In this study, a non-alcoholic fatty liver disease mouse model was established by CDAHFD diet induction. The serum AST and ALT levels of each group of mice were measured, and the liver tissue was stained with Oil Red O and HE to observe the fat accumulation and pathological changes in the liver, and to investigate the preventive and therapeutic effects of each extract of Terminalia chebula on non-alcoholic fatty liver disease. The experimental results showed that the ethanol extract group and the ethyl acetate group could significantly reduce the serum AST and ALT levels (such as Figure 1 ); the petroleum ether extract group, ethanol extract group and ethyl acetate extract group could significantly improve the accumulation of fat in the liver (such as Figure 2 ); All the extracted parts of Terminalia chebula could improve the fat vacuoles and inflammatory cell infiltration in the liver (such as Figure 3 The above results indicate that Fructus Chebulae has a certain preventive and therapeutic effect on CDAHFD-induced non-alcoholic fatty liver disease. Considering the preventive and therapeutic effects of each chemical part of Fructus Chebulae, its active ingredients should be mainly present in the ethyl acetate part.

[0052] 3. Discussion

[0053] Non-alcoholic fatty liver disease is a health problem worldwide, and "second strike" is its recognized pathogenesis. The first strike is that the body produces insulin resistance (IR), fat accumulation in the liver and lipid metabolism disorders under various factors; the second strike is the oxidation reaction, which causes liver damage, releases inflammatory factors, and leads to inflammatory response of liver cells. [ix] Many cutting-edge studies have also found that NAFLD is closely related to metabolic syndrome (MS), diabetes, cardiovascular disease, etc. [x]. The experimental results showed that during the modeling period, the extracts from various parts of Terminalia chebula had a certain improvement effect on the increased AST and ALT levels induced by CDAHFD, and also had an improvement effect on fat accumulation in liver tissue and liver damage. This may be because Terminalia chebula has rich chemical components and pharmacological effects. As mentioned earlier, Terminalia chebula is rich in tannins, polyphenols, flavonoids, etc. Studies have confirmed that these ingredients have antioxidant, antibacterial, anti-inflammatory, cholesterol absorption reducing and liver protection effects. Gallic acid, a polyphenol component of Terminalia chebula, has antioxidant and lipid-lowering effects. Studies have confirmed that within a certain concentration range, it is significantly better than vitamin C in scavenging hydroxyl free radicals, and can also inhibit lipid peroxidation reactions. [xi] Gallic acid can also inhibit the excessive formation of fat in liver tissue and reduce the levels of cholesterol and triglycerides in serum [xii] Corilagin, a tannin component of Terminalia chebula, has been shown to have an inhibitory effect on human liver cancer cells. [xiii] ; It can also protect the liver by inhibiting oxidation and apoptosis, fighting liver damage [xiv] Based on the above understanding of the pathogenesis of NAFLD, these chemical components of Terminalia chebula and their corresponding multiple pharmacological activities can reduce the accumulation of fat in the liver, reduce liver damage caused by oxidative stress, improve inflammatory response, and improve the disease condition at the overall level.

[0054] For the study and treatment of a disease, it is very important to establish an animal model similar to human lesions. First of all, the modeling method should be simple and easy to operate, with a high success rate and repetition rate, and it should not easily cause the death of the animal. Secondly, it should have the development process of the disease and conform to some basic pathological characteristics of the disease. The pathological stages of non-alcoholic fatty liver disease include simple fatty liver (NAFL), steatohepatitis (NASH), liver fibrosis, cirrhosis and hepatocellular carcinoma. [xv] A lot of research has been done on establishing the pathological model of non-alcoholic fatty liver disease. In addition to modeling through feed, there are also drug toxicity models, imaging quantitative diagnosis models, etc. [xvi] In this experiment, a NAFLD mouse model was established by inducing a high-fat diet defined by choline deficiency and L-amino acids. The experimental results showed that the liver coefficient of the model group was significantly higher than that of the blank group, the serum AST and ALT levels also increased, and fat accumulation in the liver was obvious.

[0055] In summary, the Tibetan medicine Terminalia chebula has a certain preventive and therapeutic effect on NAFLD induced by choline deficiency and L-amino acid defined high-fat diet, and the extracts of its various parts all showed certain therapeutic effects. This may be because the rich chemical components and pharmacological effects of Terminalia chebula have achieved multi-target, multi-component, and multi-mechanism improvements in NAFLD.

[0056] This experiment preliminarily confirmed the effective parts of the Tibetan medicine Terminalia chebula in the prevention and treatment of non-alcoholic fatty liver disease, providing a basis for further exploring its mechanism of action.

[0057] The relevant documents cited in this invention are as follows:

[0058] [1] Wang Jing. Advances in Traditional Chinese Medicine Treatment of Nonalcoholic Fatty Liver Disease[J]. Medical Theory and Practice, 2017, 30(12): 1747-1749.

[0059] [2] Liu Junlian. Analysis of the application value of blood lipids, blood sugar and liver function tests in the diagnosis of non-alcoholic fatty liver disease[J]. Modern Diagnosis and Treatment, 2021, 32(10): 1640-1641.

[0060] [3] Zhang Feng. Study on the effect of blood lipid serological indicators and liver function tests in the diagnosis of fatty liver[J]. Jilin Medicine, 2018, 39(9): 1639-1640.

[0061] [4] Dai Bingqing, Zhang Mingxiang. Overview of research on the treatment of non-alcoholic fatty liver disease with integrated traditional Chinese and western medicine[J]. Journal of Liaoning University of Traditional Chinese Medicine, 2017, 19(11): 139-142.

[0062] [5] Pharmacopoeia of the People's Republic of China. Chinese Pharmacopoeia Committee. Beijing: China Medical Science and Technology Press, 2020, 75.

[0063] [6] Wang Shu. Research progress on medicinal plant Terminalia chebula[J]. Anhui Agricultural Sciences, 2015, 43(5): 65-66.

[0064] [7] Xizhu Jiacuo. A brief discussion on Tibetan medicine’s understanding of liver and liver diseases[J]. Chinese Tibetology, 2010(4):155-158.

[0065] [8]Jadon A,Bhadauria M,Shukla S.Protective effect of Terminalabelerica R oxb.and gallic acid against carbon tetrachloride induced damage inalbino rats[J].J.Ethnopharmacol,2007,109(2):214-218.

[0066] [9] Chen Yongfang, Wu Zhanjun. Pathogenesis and risk factors of cholesterol gallstones in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatobiliary Diseases, 2013, 29(12): 952-955.

[0067]

[10] Zheng Sheng, Tang Yingmei. Advances in diagnosis and treatment of nonalcoholic fatty liver disease[J]. Chinese General Practice, 2013, 16(2): 117-119.

[0068]

[11] Shi Haiyan, Xi Yanli. Research progress on the biological activity of gallic acid[J]. Journal of Jilin Medical College, 2020, 41(2): 146-149.

[0069]

[12] Dludla P, Nkambule B, Jack B, et al. Inflammation and OxidativeStress in an Obese State and the Protective Effects of Gallic Acid[J]. Nutr, 2018, 11(1).

[0070]

[13] Huang ST, Yang RC, Pang J. Aqueous extract of Phyllanthus urinariainduc es apoptosis in human cancer cells [J]. Am.J.Chin.Med, 2004, 32(2): 17 5-183.

[0071]

[14] Kinoshita S, Inoue Y, Nakama S, et al. Antioxidant and hepatoprotective actions of medicinal herb, Terminalia catappa L. from OkinawaIsland and its tannin corilagin[J]. Phytomed, 2007, 14(11):755-762.

[0072]

[15] Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic Steatohepatitis:ARe view[J].JAMA, J.Am.Med.Assoc, 2020, 323(12):1175.

[0073]

[16] Zhang Yufeng, Chen Wenhui. Research on the method of establishing animal model of non-alcoholic fatty liver disease[J]. Journal of Integrated Traditional Chinese and Western Medicine for Hepatology, 2002(2):123-125.

Claims

1. Use of the ethyl acetate extract of Terminalia chebula in preparing a medicine for preventing or treating non-alcoholic fatty liver disease.

2. The use according to claim 1, characterized in that: The preparation method of the ethyl acetate extract is as follows: Take the Terminalia chebula, extract with ethanol with a concentration of more than 95%, recover ethanol from the alcohol extract, and then extract with water-petroleum ether, water-n-butanol and water-ethyl acetate solvent systems in sequence, take the ethyl acetate part, and remove the solvent to obtain the product.

3. The use according to claim 2, characterized in that: The specific operation of ethanol extraction is: use 95% ethanol in an amount 10 times the mass of Terminalia chebula to extract Terminalia chebula powder, extract 2-3 times, each time for 30-180 minutes.

4. The use according to claim 1, characterized in that: The drug is a drug for reducing the levels of ALT, AST, TG and LDL-C.

5. The use according to claim 1, characterized in that: The drug is a drug that reduces fat accumulation in the liver.

6. The use according to claim 1, characterized in that: The drug is a drug for improving liver damage. The use according to claim 1, characterized in that: The medicine is a medicine for reducing liver fat cavitation and inflammatory cell infiltration.